Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 Cells

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2141-2146

  Matsubara, Akio ^a   Teishima, Jun ^a   Mirkhat, Suichinov ^a   Yasumoto, Hiroaki ^a   Mochizuki, Hideki ^b   Seki, Mitsuhiro ^c   Mutaguchi, Kazuaki ^a   Mckeehan, Wallace L ^d   Usui, Tsuguru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b JA Hiroshima Kouseiren Hospital   (Japan)

^c Chuden Hospital   (Japan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Cell death therapy; Differentiation therapy; Gene therapy; Prostate cancer; Radiosensitivity; Tumor suppression; Tyrosine kinases

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIB;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIUM CELL; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; G2 PHASE; GAMMA RAYS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRANSFECTION;

EID: 49049103751     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Eisenberberger MA and Carducci M: Treatment of hormone-refractory prostate cancer. In: Campbell-Walsh Urology, 9th ed. Wein AJ, Kavoussi LR, Novick AC, Partin AW and Peters CA (eds.). Philadelphia, Saunders, pp. 3101-3117, 2007.
2. Yan G, Fukabori Y, Nikolaropoulos S, Wang F and McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial cell andromedin. Mol Endocrinol 6: 2123-2128, 1992.
3. Lu W, Luo Y, Kan M and McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274: 12827-12834, 1999.
4. Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J and Cunha GR: Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 40: 941-951, 1996.
5. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL and Yamanaka H: Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 46: 405-413, 1999.
6. Yan G, Fukabori Y, McBride G, Nikolaropolous S and McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13: 4513-4522, 1993.
7. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O and Berthon P: Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 52: 245-252, 2002.
8. Carstens RP, Eaton JV, Krigman HR, Walther PJ and Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 15: 3059-3065, 1997.
9. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE and Williams LT: Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12: 82-88, 1992.
10. Kan M, Uematsu F, Wu X and Wang F: Directional specificity of prostate stromal to epithelial cell communication via FGF7/FGFR2 is set by cell- and FGFR2 isoform-specific heparan sulfate. In Vitro Cell Dev Biol Anim 37: 575-577, 2001.
11. Takahashi H: Studies on the expression of fibroblast growth factors and fibroblast growth factor receptors in human prostate cancer. Nippon Hinyokika Gakkai Zasshi 89: 836-845, 1998 (in Japanese).
12. Kwabi-Addo B, Ropiquet F, Giri D and Ittmann M: Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46: 163-172, 2001.
13. Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071, 1999.
14. Feng S, Wang F, Matsubara A, Kan M and McKeehan WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 57: 5369-5378, 1997.
15. Matsubara A, Kan M, Feng S and McKeehan WL: Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 58: 1509-1514, 1998.
16. Yasumoto H, Matsubara A, Mutaguchi K, Usui T and McKeehan WL: Restoration of fibroblast growth factor receptor 2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 61: 236-242, 2004.
17. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL and Okamoto T: Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA 98: 11336-11340, 2001.
18. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP and Radvanyi F: Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18: 7234-7243, 1999.
19. Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Daly-Schveitzer N and Favre G: Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 57: 1364-1370, 1997.
20. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, Seddon AP, Cordon-Cardo C and Haimovitz-Friedman A: Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54: 2582-2590, 1994.
21. Kaighn ME, Lechner JF, Narayan KS and Jones LW: Prostate carcinoma: Tissue culture cell lines. Natl Cancer Inst Monogr 49: 17-21, 1978.
22. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225, 2003.
23. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC and Fisher PB: Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773, 2003.
24. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A and Seymour L: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-460, 2005.
25. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L and Crawford ED: The use of trastuzumab in the treatment of hormone-refractory prostate cancer; phase II trial. Prostate 60: 332-337, 2004.
26. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M and Graham J: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262, 2007.
27. National Cancer Institute. Bethesda Clinical Trials. Available from: http://www.cancer.gov/clinicaltrials. (cited 2007 September 17).
28. Wang F, McKeehan K, Yu C, Ittmann M and McKeehan WL: Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate 58: 1-12, 2004.
29. Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M and Zupi G: Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 67: 1475-1485, 2007.
30. Chendil D, Ranga RS, Meigooni D, Sathishkumar S and Ahmed MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23: 1599-1607, 2004.